Most patients with age-related macular degeneration (AMD) in a ‘real-life’ study maintained their vision or continued to improve after 5 years of treatment with ranibizumab. Medscape Medical News
Rate of Uninsured Drops by Almost 9 Million in 2014: Report
(MedPage Today) — The percentage of uninsured dropped from 13.3% to 10.4%, the Census Bureau said
Uncategorized
Rhopressa meets primary endpoint in Rocket 2 trial
Rhopressa showed non-inferiority to timolol in glaucoma patients with baseline IOP below 25 mm Hg in a phase 3 clinical trial, Aerie Pharmaceuticals announced.Vicente Anido Jr., PhD, CEO of Aerie, reviewed results of the Rocket 2 trial during a company…
Campaign ’16: GOP Candidates Have Little to Say About Health
(MedPage Today) — Candidates discuss medical marijuana, vaccines
Uncategorized
VIDEO: Speaker discusses new data on FluidVision accomodative IOL
BARCELONA — At the European Society of Cataract and Refractive Surgeons meeting, Louis D. “Skip” Nichamin, MD, reported 2-year follow-up data on the PowerVision FluidVision accomodative IOL.
Presbia Flexivue Microlens™ Implanted in More Than 1,000 Patients Worldwide
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic medical device company and leader in near-vision restoration announced today that more than 1000 patients worldwide have been treated with the Presbia Flexivue Microlens™. “We are very pleased to announce this significant milestone,” said Todd Cooper, President and CEO of Presbia. “As we expand the commercialization of our Microlens into additional countries around the world, we are thrilled by the feedback we are receiving from